https://www.mynewsdesk.com/se/astellas-pharma/pressreleases Mynewsdesk nyhetsfeed direkt från källan https://www.mynewsdesk.com/se/astellas-pharma/pressreleases https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png 128 23 sv 15 Mon, 08 Dec 2025 09:00:00 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-vyloy-i-kombination-med-kemoterapi-vid-cancer-i-magsaecken-eller-gastroesofageala-oevergaangen-3420383?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-vyloy-i-kombination-med-kemoterapi-vid-cancer-i-magsaecken-eller-gastroesofageala-oevergaangen-3420383?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Wed, 20 Aug 2025 09:02:45 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/padcev-enfortumab-vedotin-plus-keytruda-pembrolizumab-significantly-improves-survival-for-certain-patients-with-bladder-cancer-when-given-before-and-after-surgery-3399869?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/padcev-enfortumab-vedotin-plus-keytruda-pembrolizumab-significantly-improves-survival-for-certain-patients-with-bladder-cancer-when-given-before-and-after-surgery-3399869?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Thu, 26 Sep 2024 09:32:53 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-vyloy-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3345233?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-vyloy-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3345233?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Tue, 03 Sep 2024 09:08:35 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-som-foersta-linjens-behandling-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3340296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-som-foersta-linjens-behandling-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3340296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Wed, 31 Jul 2024 09:50:36 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-faar-positivt-chmp-utlaatande-foer-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3335796?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-faar-positivt-chmp-utlaatande-foer-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3335796?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Fri, 05 Jul 2024 08:30:00 +0200 Svenska kvinnor googlar hellre än att fråga vården enligt en ny Novus-undersökning om klimakteriet. 34% upplever sig ha ingen eller begränsad kunskap om klimakteriet och 57% anser att deras kunskap om behandlingsalternativ är begränsad. Nästan hälften av kvinnorna att de känner oro relaterat till klimakteriebesvär, vilket påverkar både arbets- och privatlivet. Stödet från vården behöver öka. https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/klimakteriet-beroer-haelften-av-befolkningen-ny-novus-undersoekning-visar-paa-behovet-av-oekat-stoed-och-kunskap-fraan-vaarden-3333259?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/klimakteriet-beroer-haelften-av-befolkningen-ny-novus-undersoekning-visar-paa-behovet-av-oekat-stoed-och-kunskap-fraan-vaarden-3333259?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Fri, 17 May 2024 12:26:46 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/tlv-beslut-veoza-ingaar-i-hoegkostnadsskyddet-foer-patienter-som-inte-kan-behandlas-med-hormoner-3323673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/tlv-beslut-veoza-ingaar-i-hoegkostnadsskyddet-foer-patienter-som-inte-kan-behandlas-med-hormoner-3323673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Fri, 22 Mar 2024 14:34:45 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-xtandi-enzalutamid-foer-behandling-av-hoegriskpatienter-med-aaterfall-vid-tidig-prostatacancer-i-eu-3312635?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-xtandi-enzalutamid-foer-behandling-av-hoegriskpatienter-med-aaterfall-vid-tidig-prostatacancer-i-eu-3312635?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Tue, 12 Dec 2023 11:46:42 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-kommissionen-godkaenner-veoza-fezolinetant-foer-behandling-av-maattliga-till-svaara-vasomotoriska-symtom-vms-i-samband-med-menopaus-3292518?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-kommissionen-godkaenner-veoza-fezolinetant-foer-behandling-av-maattliga-till-svaara-vasomotoriska-symtom-vms-i-samband-med-menopaus-3292518?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Sun, 22 Oct 2023 16:30:00 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/resultat-fraan-fas-3-studie-ev-302-visar-signifikant-foerlaengd-oeverlevnad-foer-behandling-med-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-hos-patienter-med-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3281210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/resultat-fraan-fas-3-studie-ev-302-visar-signifikant-foerlaengd-oeverlevnad-foer-behandling-med-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-hos-patienter-med-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3281210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Thu, 19 Oct 2023 09:23:13 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/new-england-journal-of-medicine-publicerar-astellas-resultat-fraan-fas-iii-studien-embark-som-utvaerderar-xtanditm-enzalutamid-hos-hoegriskpatienter-efter-biokemiskt-aaterfall-med-icke-metastaserad-prostatacancer-3280666?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/new-england-journal-of-medicine-publicerar-astellas-resultat-fraan-fas-iii-studien-embark-som-utvaerderar-xtanditm-enzalutamid-hos-hoegriskpatienter-efter-biokemiskt-aaterfall-med-icke-metastaserad-prostatacancer-3280666?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Mon, 16 Oct 2023 12:26:03 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-to-share-new-data-across-hard-to-treat-cancers-during-esmo-congress-2023-3279837?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-to-share-new-data-across-hard-to-treat-cancers-during-esmo-congress-2023-3279837?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Mon, 16 Oct 2023 07:30:00 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-veozatm-fezolinetant-foer-godkaennande-i-eu-3279729?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-veozatm-fezolinetant-foer-godkaennande-i-eu-3279729?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Wed, 05 Jul 2023 13:02:36 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/positiva-topline-resultat-fraan-fas-3b-studie-med-fezolinetant-foer-behandling-av-vaermevallningar-och-slash-eller-nattsvettningar-vasomotoriska-symptom-vms-vid-menopaus-3263474?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/positiva-topline-resultat-fraan-fas-3b-studie-med-fezolinetant-foer-behandling-av-vaermevallningar-och-slash-eller-nattsvettningar-vasomotoriska-symptom-vms-vid-menopaus-3263474?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Thu, 29 Jun 2023 15:43:26 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/underhaallsbehandling-med-gilteritinib-foerdelaktigt-foer-subgrupp-av-patienter-med-flt3-positiv-akut-myeloisk-leukemi-3262629?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/underhaallsbehandling-med-gilteritinib-foerdelaktigt-foer-subgrupp-av-patienter-med-flt3-positiv-akut-myeloisk-leukemi-3262629?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Thu, 23 Mar 2023 15:57:37 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/xtandi-enzalutamid-och-leuprorelin-i-kombination-foerbaettrar-signifikant-metastasfri-oeverlevnad-hos-patienter-med-icke-metastaserad-prostatacancer-enligt-fas-iii-studien-embark-3241900?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/xtandi-enzalutamid-och-leuprorelin-i-kombination-foerbaettrar-signifikant-metastasfri-oeverlevnad-hos-patienter-med-icke-metastaserad-prostatacancer-enligt-fas-iii-studien-embark-3241900?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Wed, 22 Mar 2023 09:50:32 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-positive-findings-from-phase-3-glow-trial-of-zolbetuximab-during-march-asco-plenary-series-3241312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-positive-findings-from-phase-3-glow-trial-of-zolbetuximab-during-march-asco-plenary-series-3241312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Tue, 24 Jan 2023 09:28:17 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/asco-gi-astellas-presenterar-positiva-resultat-foer-zolbetuximab-fraan-fas-3-studien-spotlight-3229291?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/asco-gi-astellas-presenterar-positiva-resultat-foer-zolbetuximab-fraan-fas-3-studien-spotlight-3229291?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Mon, 09 Jan 2023 08:59:23 +0100 NT-rådet rekommenderar användande av PADCEV som monoterapi vid behandling av vuxna patienter med lokalt avancerad eller metastaserad urotelial cancer som tidigare har fått platinainnehållande kemoterapi och en PD-(L)1-hämmare. https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-padcev-som-monoterapi-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3226545?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-padcev-som-monoterapi-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3226545?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma Mon, 21 Nov 2022 14:24:01 +0100 Astellas Pharma announced positive topline results from the Phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-zolbetuximab-meets-primary-endpoint-in-phase-3-spotlight-trial-as-first-line-treatment-in-claudin18-punkt-2-positive-her2-negative-locally-advanced-or-metastatic-gastric-and-gastroesophageal-junction-gej-cancers-3218817?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-zolbetuximab-meets-primary-endpoint-in-phase-3-spotlight-trial-as-first-line-treatment-in-claudin18-punkt-2-positive-her2-negative-locally-advanced-or-metastatic-gastric-and-gastroesophageal-junction-gej-cancers-3218817?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Astellas Pharma